D-type cyclins serve as cell cycle recipients of several oncogenic pathways. The specific sequences of the promoters of the cyclin D genes are thought to render particular D-cyclins responsive to specific oncogenic pathways. For instance, the Ras oncogene was postulated to signal through cyclin D1, while Myc can impact the cell cycle machinery by transcriptionally upregulating cyclin D2. In the current study we engineered mouse fibroblasts to express only cyclin D1, only D2, or only D3. These 'single-cyclin' cells allowed us to rigorously test the ability of cyclin D1, D2, or D3, when expressed on their own, to serve as recipients of the Ras-and Myc-driven oncogenic pathways. We found that each of the D-cyclins was sufficient to drive oncogenic proliferation of mouse fibroblasts. This, together with our recent observations that cells lacking all three D-cyclins show greatly reduced susceptibility to the oncogenic action of Ras and Myc, reveals that the Ras and Myc oncogenes can impact the core cell cycle machinery through all three D-cyclins.
The core cell cycle machinery represents the ultimate recipient of the oncogenic signals. Several mitogenic and oncogenic pathways signal to the cell cycle machinery through D-type cyclins (Sherr and Roberts, 1999) . This family of cyclins is composed of three related proteins, cyclin D1, D2, and D3, which are expressed in a largely overlapping fashion in virtually all proliferating cell types (Bartkova et al., 1998) .
One of the important challenges is to decipher how various oncogenic signals impact the core cell cycle machinery. For instance, the Ras oncogene was shown to act via cyclin D1, by activating c-Jun and c-Ets transcription factors that interact directly with AP-1-and Ets-binding sites within the cyclin D1 promoter (Filmus et al., 1994; Albanese et al., 1995; Liu et al., 1995; Lavoie et al., 1996; Marshall, 1999; Amanatullah et al., 2001) . Other oncogenic pathways that were shown to act specifically through cyclin D1 include c-ErbB2 oncogene (acting through Sp1 and E2F transcription factors impinging on cyclin D1 promoter (Lee et al., 2000) , Src (via CREB/ATF-2 binding sites (Lee et al., 1999) , Pak1 (through NFkB sites; Balasenthil et al., 2004) , protein kinase C (through c-Jun and AP-1 site; Soh and Weinstein, 2003) , Wnt-b catenin pathway (through LEF-1 binding site; Shtutman et al., 1999; Tetsu and McCormick, 1999; Terada et al., 2003) , phosphatidylinositol-3 kinase (PI3K) and IKKa (both though TCF/LEF; Albanese et al., 2003) . In addition to this transcriptional mechanism, the accumulation of cyclin D1 was also shown to be controlled at the level of protein stability, through phosphorylation of cyclin D1 at threonine 286 by the glycogen synthase kinase 3b (GSK3b) (Diehl et al., 1998; Alt et al., 2000) . Moreover, PI3K/Akt pathway was demonstrated to increase the stability of cyclin D1 mRNA (Dufourny et al., 2000) and to enhance its translation rate (Muise-Helmericks et al., 1998) , while the MAPK pathway was shown to control the assembly of cyclin D1-CDK4 complexes .
The Myc oncogene, on the other hand, was reported to promote cell cycle progression by transcriptional upregulation of cyclin D2 (Bouchard et al., 1999 (Bouchard et al., , 2001 Coller et al., 2000; Dey et al., 2000; ) . Myc was shown to bind the cyclin D2 promoter in vivo and to induce cyclin D2 expression and histone acetylation at a single nucleosome site in a MycBoxII-TRRAP-dependent manner (Bouchard et al., 2001 (Bouchard et al., , 2004 . However, others found that the c-Myc oncogene impinges on the cell cycle machinery via cyclins D1 and D2 (Perez-Roger et al., 1999) . These latter observations are consistent with the findings that in cerebellar granule neuron precursors, the related N-Myc transcription factor induces cyclins D1 and D2 (Ciemerych et al., 2002) . A potential limitation of these analyses is that they were performed in different cell types, which often expressed only a subset of the three D-type cyclins.
In the experiments described below, we decided to rigorously test the requirement for individual D-cyclins in transmitting specific oncogenic signals to the cell cycle machinery. We decided to focus our analyses on mouse embryonal fibroblasts (MEFs), as this cell type normally expresses all three D-type cyclins. We recently reported that MEFs in which all three D-cyclins had been ablated showed greatly reduced sensitivity to the oncogenic transformation by the Ras and Myc oncogenes (Kozar et al., 2004 ). In the current study, we engineered MEFs expressing only cyclin D1, only D2, or only D3. We next tested the ability of each of these cyclins to mediate proliferative action of the specific oncogenic pathways.
To obtain cells expressing a single D-type cyclin, we interbred cyclin D1-, D2-, or D3-deficient strains of mice (Sicinski et al., 1995 (Sicinski et al., , 1996 Sicinska et al., 2003) , and we generated cyclin D1
Crossing of these heterozygotes yielded cyclin D2
(cyclin D2-only), and D1 
À/À cells ( Figure 1a ). We next asked whether the remaining, intact D-type cyclin was upregulated in 'single-cyclin' MEFs. We found that the levels of D-cyclins seen in 'single-cyclin' cells closely matched those observed in wild-type MEFs ( Figure 1b) .
We also determined that the levels of other components of the core cell cycle machinery, such as cyclins A and E, CDK2, CDK4 and CDK6 were not altered in the mutant cells, except for a reduction of p27
Kip1 and p21
Cip1 levels. Likewise, we found that that cyclin E-and cyclin A-associated kinase activities were essentially unchanged in 'single-cyclin' cells ( Figure 1c , and data not shown). We concluded that the 'single-cyclin' cells did not undergo major rearrangements of the core cell cycle machinery.
Since the c-Myc oncogene was postulated to signal through cyclin D2 (Bouchard et al., 1999 (Bouchard et al., , 2001 Coller et al., 2000; Dey et al., 2000) , we analysed the ability of cells expressing only cyclin D2 to respond to c-Mycdriven proliferative signals, and we compared the response to that seen in cells expressing only cyclin D1, or only cyclin D3. We first infected cells with retroviruses encoding c-Myc, or with control empty vectors, and we scored the ability of c-Myc to enhance cell proliferation.
As expected, wild-type MEFs responded to c-Myc expression with a proliferative burst. Cyclin D2-only cells also proliferated vigorously in response to c-Myc, consistent with the notion that c-Myc signals through cyclin D2. However, cells expressing only cyclin D1, or only D3 responded equally well to Analyses of cyclin D levels revealed that wild-type MEFs upregulated cyclins D1, D2, and -to a lesser degree -also D3 in response to c-Myc expression. Similar upregulation of cyclins D1, or D2, or D3 was observed in 'single-cyclin' MEFs (Figure 4a ). These results suggest that upregulation of a single D-cyclin is sufficient to mediate the oncogenic action of c-Myc.
We next turned our attention to the Ras oncogene, which was reported to signal through cyclin D1 (Filmus et al., 1994; Albanese et al., 1995; Liu et al., 1995; Lavoie et al., 1996; Marshall, 1999; Amanatullah et al., 2001 ). (Bouchard et al., 1999) or with an empty vector, and selected for 10 days in Hygromycin B (Calbiochem, 150 mg/ml). Cells were plated at 10 4 per well of 12 well plates and cell numbers were scored every other day. (b) The Myc-driven proliferative burst was presented as a ratio of fold increase in cell numbers observed in MEFs expressing c-Myc to fold increase in cell numbers observed in MEFs infected with an empty vector, during 7 days observation period. Shown is a representative experiment (out of three) (c) MEFs were infected with a retrovirus encoding c-Myc, or with an empty vector. 10 4 cells were plated per 6 cm plate. Colonies were stained with crystal violet and enumerated after 2-3 weeks. (d) Quantification of the numbers of colonies. Shown are combined results of three independent experiments. The number of colonies seen in wild-type cells was set as 100%. Error bars represent s.d.
We infected cells with retroviruses expressing activated, oncogenic v-Ha-Ras along with dominant negative p53. We then plated cells in monolayers and we scored the formation of the transformed foci.
As expected, monolayers of wild-type cells formed numerous foci upon expression of the oncogenic Ras. Consistent with the reports that Ras signals through cyclin D1, we observed numerous foci in cyclin D1-only cells. However, we also encountered high numbers of foci in cells expressing only cyclin D2 or only cyclin D3 (Figure 3a and b) . Together with our earlier observations that MEFs lacking all three D-cyclins show greatly reduced susceptibility to Ras-driven transformation (Kozar et al., 2004) , these results suggest that in fibroblasts the Ras oncogene can impinge the core cell cycle machinery not only through cyclin D1, but also via cyclins D2 or D3.
We also infected cells with retroviruses encoding Ras plus E1A oncoprotein. Again, we observed transformed foci in cells expressing only cyclin D1, only D2, or only D3 (Figures 3c and d) . These findings reinforced our conclusion that the oncogenic Ras can drive cell proliferation through all three D-type cyclins.
Analyses of cyclin D levels revealed that in wild-type cells, the Ras oncogene causes strong upregulation of cyclin D1, but not D2 or D3. Likewise, we observed strong upregulation of cyclin D1 by Ras in cyclin D1-only cells (Figure 4b) . Surprisingly, while cyclin D2-only and D3-only cells remained susceptible to Ras-driven transformation (Figure 3) , Ras oncogene failed to upregulate cyclins D2 or D3 in these cells (Figure 4b ). Together with our earlier observations that MEFs lacking all three D-cyclins show greatly reduced susceptibility to Ras-driven transformation (Kozar et al., 2004) , these results suggest that the presence (rather than induction) of cyclins D2 or D3 is essential for Ras-induced transformation.
It has been postulated that the specific sequences of the promoters of the cyclin D genes render particular D-cyclins responsive to particular oncogenic pathways. While most of the oncogenic pathways studied were ascribed to act via cyclin D1 (see above), several others were postulated to signal specifically through cyclin D2 (Bouchard et al., 1999 (Bouchard et al., , 2001 (Bouchard et al., , 2004 Huang et al., 2001; Friedrichsen et al., 2003; Virolle et al., 2003; Hurt et al., 2004) or cyclin D3 (Yang et al., 1998; Malstrom et al., 2001; Hsia et al., 2002; Sicinska et al., 2003) .
In order to study the requirement for D-cyclins in specific oncogenic pathways, we and others generated mice lacking individual D-cyclin genes (Fantl et al., 1995; Sicinski et al., 1995 Sicinski et al., , 1996 Sicinska et al., 2003) . We found that cyclin D1-deficient mice were resistant to breast cancers driven by the Ras and c-ErbB-2 oncogenes (Yu et al., 2001) . On the other hand, cyclin D1-null mice remained susceptible to Ras-driven salivary gland tumors, while cyclin D1 À/À MEFs were susceptible to the malignant transformation by the oncogenic Ras (Yu et al., 2001) . We noted that the mammary epithelial luminal cells express cyclin D1 as a sole D-type cyclin, while salivary glands and fibroblasts express also cyclins D2 and D3 (Yu et al., 2001) . Hence, one interpretation of these findings is that the c-ErbB-2-Ras pathway can access the cell cycle machinery only through the D-type cyclin(s) that are normally expressed in a given cell type.
In the work presented here, we rigorously tested the ability of cyclin D1, or D2, or D3, when expressed on their own, to serve as recipients of the specific oncogenic pathways. We found that MEFs expressing single D-type cyclins responded normally to the oncogenic action of Myc or Ras. Hence, in these cells, the Myc and Ras oncogenes can signal through all three D-cyclins. Indeed, we observed upregulation of all thee D-type cyclins in response to c-Myc expression. Myc oncogene, in addition to transcriptionally upregulating the expression of the cyclin D2 gene, might also act via posttranscriptional mechanisms on other D-cyclins. Indeed, Myc was shown to increase cyclin D2 and D1 protein synthesis rates (Perez-Roger et al., 1999) , and it might employ similar mechanisms to upregulate cyclin D3.
Surprisingly, we observed that the Ras oncogene can signal in cyclin D2-only and in D3-only cells without significantly inducing cyclins D2 and D3. Hence, the Ras oncogene can utilize the individual D-cyclins without upregulating their levels. We note that activation of the Ras-MAPK pathway was shown to increase association of cyclin D1 with CDK4 . Hence, the Ras oncogene might increase interaction of cyclins D2 and D3 with their catalytic partners, CDK4 and CDK6. The Ras pathway might also affect cyclin D-CDK complexes by augmenting their kinase activity via other post-translational mechanisms, such as phosphorylation of the CDK subunit, or association with cell cycle inhibitors. Elucidation of the exact molecular components of the pathways that link Ras and Myc with particular D-type cyclins is important in order to interfere with the proliferative action of these oncogenes in human tumor cells. 
